zurück
Amivantamab (non-small cell lung cancer (NSCLC), EGFR exon 20 insertion mutations, after platinum-based therapy)
Subject:
- Active Substance: Amivantamab
- Name: Rybrevant®
- Therapeutic area: Non-small cell lung cancer (NSCLC)
- Pharmaceutical company: Janssen-Cilag GmbH
Time table:
- Start: 15.01.2022
- Final decision by G-BA: 07.07.2022
Final decision:
- Patients who are eligible for another chemotherapy:
- No additional benefit proved
- Patients who are not eligible for another chemotherapy:
- No additional benefit proved